United Therapeutics Other accrued liabilities increased by 38.8% to $100.80M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 34.8%, from $154.50M to $100.80M. Over 5 years (FY 2020 to FY 2025), Other accrued liabilities shows an upward trend with a 12.9% CAGR.
Significant fluctuations may indicate changes in business model, such as shifts in deferred revenue recognition or changes in short-term regulatory obligations.
This category includes miscellaneous short-term obligations that are not classified under accounts payable or accrued li...
Commonly used as a catch-all for short-term liabilities; varies by industry and business model.
current_liabilities_other_liabilities_current| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $24.80M | $26.00M | $28.40M | $60.80M | $39.60M | $35.70M | $32.50M | $38.60M | $37.80M | $70.10M | $71.00M | $126.30M | $77.80M | $80.10M | $93.60M | $154.50M | $95.10M | $78.30M | $72.60M | $100.80M |
| QoQ Change | — | +4.8% | +9.2% | +114.1% | -34.9% | -9.8% | -9.0% | +18.8% | -2.1% | +85.4% | +1.3% | +77.9% | -38.4% | +3.0% | +16.9% | +65.1% | -38.4% | -17.7% | -7.3% | +38.8% |
| YoY Change | — | — | — | — | +59.7% | +37.3% | +14.4% | -36.5% | -4.5% | +96.4% | +118.5% | +227.2% | +105.8% | +14.3% | +31.8% | +22.3% | +22.2% | -2.2% | -22.4% | -34.8% |